See the latest news and media coverage for Neurimmune. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biopharmaceutical company developing antibody therapies for protein aggregation diseases
neurimmune.comLast updated
In short: Neurimmune sold cliramitug royalty rights to Royalty Pharma for up to $425 million.
The capital will fund a proof-of-concept clinical trial for NG004, an experimental antibody designed to promote nerve regeneration in patients with acute spinal cord injuries.
The Phase 1b trial demonstrates amyloid depletion and improved cardiac function without serious adverse events for the investigational antibody.
The deal includes $125M upfront and milestone payments, providing non-dilutive funding for R&D pipeline.
Exclusive global license agreement targets lambda light chain fibrils in AL amyloidosis. Neurimmune receives upfront payment, up to $780 million milestones, and royalties.
Cliramitug is an investigational human monoclonal antibody discovered by Neurimmune and designed to deplete amyloid deposits from affected hearts in patients with amyloid transthy...
Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a portion of Neurimmune’s royalty interest in AstraZeneca’s cliramitug for up to $425 million...
Plus, news about Pliant Therapeutics, Replicate Bioscience, Denali, Laigo Bio and Auxilius Pharma.
Shots: Neurimmune has entered into an exclusive global collaboration & licensing deal with Alexion to develop NI009, a preclinical human mAb for the treatment of...
Track Neurimmune and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Neurimmune and other trending companies.
